Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coya Therapeutics, Inc. (COYA)
NASDAQ:COYA
RESEARCH TOOLSreports
Coya Therapeutics, Inc. (COYA) Stock Price & Analysis
36 Followers
COYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.21 - $10.69
Previous Close$7.17
Volume50.49K
Average Volume (3M)52.43K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$32.60M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 06, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding14,618,172
10 Day Avg. Volume78,208
30 Day Avg. Volume52,427
Standard Deviation0.20
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.48
Price to Sales (P/S)14.73
Price to Cash Flow (P/CF)-9.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$16.50Price Target Upside136.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Coya Therapeutics, Inc. News
PremiumCompany Announcements
Coya Therapeutics Financial and Operational Results Overview
Bulls Say, Bears Say
Bulls Say
Financial StabilityCOYA Therapeutics has significantly increased its cash position, enhancing its financial stability and ability to fund operations into the future.
Innovation And Market PotentialThe advancement and targeted approach of COYA 302 for multiple neurodegenerative diseases shows promise for future development and potential market success.
Regulatory EnvironmentThe FDA's positive response to the role of biomarkers in neurology indicates a regulatory environment that may be favorable to Coya's approach.
Bears Say
Disease UnderstandingALS remains one of the most poorly understood neurodegenerative diseases, creating challenges for treatment and prognosis.
Drug Development ChallengesRecent trial failures in ALS treatments highlight the complexity of the disease and the need for novel approaches.
Treatment SetbacksThe failure of Relyvrio in ALS represents a significant setback in understanding and treating this aggressive disease.
---
Ownership Overview
6.67% Insiders
6.14% Mutual Funds
5.64% Other Institutional Investors
81.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
COYA FAQ
What was Coya Therapeutics, Inc.’s price range in the past 12 months?
Coya Therapeutics, Inc. lowest stock price was $3.21 and its highest was $10.69 in the past 12 months.
What is Coya Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Coya Therapeutics, Inc.’s upcoming earnings report date?
Coya Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2024 which is in 18 days.
How were Coya Therapeutics, Inc.’s earnings last quarter?
Coya Therapeutics, Inc. released its earnings results on May 09, 2024. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.05.
Is Coya Therapeutics, Inc. overvalued?
According to Wall Street analysts Coya Therapeutics, Inc.’s price is currently Undervalued.
Does Coya Therapeutics, Inc. pay dividends?
Coya Therapeutics, Inc. does not currently pay dividends.
What is Coya Therapeutics, Inc.’s EPS estimate?
Coya Therapeutics, Inc.’s EPS estimate is -$0.17.
How many shares outstanding does Coya Therapeutics, Inc. have?
Coya Therapeutics, Inc. has 15,221,308 shares outstanding.
What happened to Coya Therapeutics, Inc.’s price movement after its last earnings report?
Coya Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went down -2.955%.
Which hedge fund is a major shareholder of Coya Therapeutics, Inc.?
Among the largest hedge funds holding Coya Therapeutics, Inc.’s share is Greenlight Capital Inc. It holds Coya Therapeutics, Inc.’s shares valued at 13M.
---
Coya Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.50 (136.05% Upside)
$16.50 (136.05% Upside)
Blogger Sentiment
Bullish
COYA Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 9.7%
Last 30 Days ▼ 9.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
68.70%
12-Months-Change
Fundamentals
Return on Equity
-42.32%
Trailing 12-Months
Asset Growth
115.53%
Trailing 12-Months
Company Description
Coya Therapeutics, Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
---
COYA Stock 12 Month Forecast
Average Price Target
$16.50
▲(136.05% Upside)
Technical Analysis
Best Analysts Covering COYA
1 Year
1 Year Success Rate
11/12 ratings generated profit
1 Year Average Return
+54.47%
reiterated a buy rating 4 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +54.47% per trade.
---